Settlement agreement restricts generic market due to FDA approval of oral non-statin medicines, leading to ongoing patent litigation against Renata Limited.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Settlement agreement restricts generic market due to FDA approval of oral non-statin medicines, leading to ongoing patent litigation against Renata Limited.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
- FDA
Related events
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- Litigation regarding FDA approval process.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- The FDA has questioned promotional materials related to an investigational drug from Alar Pharmaceuticals.
Coverage
Newest first; wire copies grouped- Unknown outlet